Meta-analyses show copper dyshomeostasis in Alzheimer’s disease. However, a study evaluating copper changes in other neurodegenerative forms of dementia has not yet been performed. In this study, we assessed copper, ceruloplasmin, copper not bound to ceruloplasmin, and copper to ceruloplasmin ratio in 85 patients affected by frontotemporal lobar degeneration (FTLD) and 55 healthy controls. Data were analyzed through multivariate ANOVA models taking into account age and sex as covariates and the stratification for FTLD variants, after calculating power analysis to ensure the reliability of the conclusions drawn. The study revealed no difference between the groups.
BurrellJR, KiernanMC, VucicS, HodgesJR (2011) Motor neuron dysfunction in frontotemporal dementia, Brain134, 2582–2594.
4.
JosephsKA, PetersenRC, KnopmanDS, BoeveBF, WhitwellJL, DuffyJR, ParisiJE, DicksonDW (2006) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP, Neurology66, 41–48.
5.
Lomen-HoerthC, AndersonT, MillerB (2002) The overlap of amyotrophic lateral sclerosis and frontotemporal dementia, Neurology59, 1077–1079.
6.
RohrerJD, GuerreiroR, VandrovcovaJ, UphillJ, ReimanD, BeckJ, IsaacsAM, AuthierA, FerrariR, FoxNC, MackenzieIR, WarrenJD, de SilvaR, HoltonJ, ReveszT, HardyJ, MeadS, RossorMN (2009) The heritability and genetics of frontotemporal lobar degeneration, Neurology73, 1451–1456.
7.
BucossiS, VentrigliaM, PanettaV, SalustriC, PasqualettiP, MarianiS, SiottoM, RossiniPM, SquittiR (2011) Copper in Alzheimer’s disease: A meta-analysis of serum, plasma, and cerebrospinal fluid studies, J Alzheimers Dis24, 175–185.
8.
LiD-D, ZhangW, WangZ-Y, ZhaoP (2017) Serum copper, zinc, and iron levels in patients with Alzheimer’s disease: A meta-analysis of case-control studies, Front Aging Neurosci9, 300.
9.
SchragM, MuellerC, OyoyoU, SmithMA, KirschWM (2011) Iron, zinc and copper in the Alzheimer’s disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion, Prog Neurobiol94, 296–306.
WangZX, TanL, WangHF, MaJ, LiuJ, TanMS, SunJH, ZhuXC, JiangT, YuJT (2015) Serum iron, zinc, and copper levels in patients with Alzheimer’s disease: A replication study and meta-analyses, J Alzheimers Dis47, 565–581.
12.
SquittiR, GhidoniR, SimonelliI, IvanovaID, ColabufoNA, ZuinM, BenussiL, BinettiG, CassettaE, RongiolettiM, SiottoM (2018) Copper dyshomeostasis in Wilson disease and Alzheimer’s disease as shown by serum and urine copper indicators, J Trace Elem Med Biol45, 181–188.
FostinelliS, CianiM, ZanardiniR, ZanettiO, BinettiG, GhidoniR, BenussiL (2018) The heritability of frontotemporal lobar degeneration: Validation of pedigree classification criteria in a Northern Italy cohort, J Alzheimers Dis61, 753–760.
15.
GhidoniR, StoppaniE, RossiG, PiccoliE, AlbertiniV, PaterliniA, GlionnaM, PegoianiE, AgnatiLF, FenoglioC, ScarpiniE, GalimbertiD, MorbinM, TagliaviniF, BinettiG, BenussiL (2012) Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: A multicenter Italian study, Neurodegener Dis9, 121–127.
16.
BenussiL, GhidoniR, PegoianiE, MorettiDV, ZanettiO, BinettiG (2009) Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide, Neurobiol Dis33, 379–385.
WalsheJM, Clinical Investigations Standing Committee of the Association of Clinical Biochemists (2003) Wilson’s disease: The importance of measuring serum caeruloplasmin non-immunologically, Ann Clin Biochem40, 115–121.
SquittiR, PasqualettiP, PolimantiR, SalustriC, MoffaF, CassettaE, LupoiD, VentrigliaM, CortesiM, SiottoM, VernieriF, RossiniPM (2013) Metal-score as a potential non-invasive diagnostic test for Alzheimer’s disease, Curr Alzheimer Res10, 191–198.
25.
SquittiR (2012) Copper dysfunction in Alzheimer’s disease: From meta-analysis of biochemical studies to new insight into genetics, J Trace Elem Med Biol26, 93–96.
26.
JamesSA, VolitakisI, AdlardPA, DuceJA, MastersCL, ChernyRA, BushAI (2012) Elevated labile Cu is associated with oxidative pathology in Alzheimer disease, Free Radic Biol Med52, 298–302.
27.
RembachA, HareDJ, LindM, FowlerCJ, ChernyRA, McLeanC, BushAI, MastersCL, RobertsBR (2013) Decreased copper in Alzheimer’s disease brain is predominantly in the soluble extractable fraction, Int J Alzheimers Dis2013, 623241.
28.
KeppKP (2017) Alzheimer’s disease: How metal ions define β-amyloid function, Coord Chem Rev351127–159.
29.
SquittiR, SalustriC, RongiolettiM, SiottoM (2017) Commentary: The case for abandoning therapeutic chelation of copper ions in Alzheimer’s disease, Front Neurol8, 503.
30.
GazzinaS, PremiE, ZanellaI, BiasiottoG, ArchettiS, CossedduM, ScarpiniE, GalimbertiD, SerpenteM, GasparottiR, PadovaniA, BorroniB (2016) Iron in frontotemporal lobar degeneration: A new subcortical pathological pathway?. Neurodegener Dis16, 172–178.
31.
SheelakumariR, KesavadasC, VargheseT, SreedharanRM, ThomasB, VergheseJ, MathuranathPS (2017) Assessment of iron deposition in the brain in frontotemporal dementia and its correlation with behavioral traits, AJNR Am J Neuroradiol38, 1953–1958.
32.
SquittiR, SiottoM, CassettaE, IdrissiIG, ColabufoNA (2017) Measurements of serum non-ceruloplasmin copper by a direct fluorescent method specific to Cu(II), Clin Chem Lab Med55, 1360–1367.
